Inflammatix Secures $57 Million in Funding as It Awaits FDA Approval for AI-Driven Sepsis Diagnostic Test

Funding:
Inflammatix has raised $57 million in Series E financing, bringing its total funding to over $200 million.

FDA Approval:
The company is awaiting FDA review for its AI-powered sepsis test, which aims to improve detection and treatment of this life-threatening condition.

Company Size:
Inflammatix is a roughly 80-person company, indicating a significant investment in its technology and growth potential.

Regulatory Context:
The FDA's reclassification plans for in vitro diagnostics (IVDs) may reduce regulatory burdens for test developers like Inflammatix, but specific implications remain unclear.

Market Impact:
The approval and commercialization of Inflammatix's sepsis test could significantly impact the medical diagnostics industry, particularly in the area of infectious disease detection.